Results 11 to 20 of about 4,251 (181)
Haematologica, 2021 B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients.
Kerry A. Rogers +13 more
doaj +3 more sources
Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
Zhongliu Fangzhi Yanjiu, 2022 Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use.
LIANG Cuilyu, ZHANG Yin, CHEN Qiying
doaj +2 more sources
The role of acalabrutinib in adults with chronic lymphocytic leukemia [PDF]
Therapeutic Advances in Hematology, 2021 The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic
Bita Fakhri, Charalambos Andreadis
doaj +2 more sources
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. [PDF]
PLoS ONE, 2016 Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.
Bonnie K Harrington +18 more
doaj +2 more sources
Acalabrutinib Approved for MCL [PDF]
Cancer Discovery, 2018 Abstract The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.
openaire +3 more sources
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI [PDF]
Haematologica, 2018 Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson +14 more
doaj +2 more sources
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
Haematologica, 2019 While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series +6 more
doaj +3 more sources
Haematologica, 2021 Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL).
Jennifer R. Brown +14 more
doaj +3 more sources
Therapeutic Advances in HematologyBackground: Acalabrutinib is a highly selective, latest generation Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Mengya Li +6 more
doaj +2 more sources
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]
Blood Advances, 2017 : The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib.
Alexander P. Bye +10 more
doaj +2 more sources